(FBZ) |
| 0 (0%) 10-10 19:06 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 12.20 |
| Resistance 1: | 11.92 |
| Pivot price: | 11.74 |
| Support 1: | 11.46 |
| Support 2: | 9.53 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Mon, 07 Jul 2025
Fenbendazole induces pyroptosis in breast cancer cells through HK2/caspase-3/GSDME signaling pathway - Frontiers
Thu, 15 May 2025
Comparative study of Hot-Melt Extrusion, spray drying, and KinetiSol® processing to formulate a poorly water-soluble and thermolabile drug - ScienceDirect.com
Tue, 13 May 2025
FBZ: This Enhanced Product Is Flawed, More Sensible To Pursue EWZ - Seeking Alpha
Fri, 14 Mar 2025
Armel and Jabz to stand in for BOOM Esports ahead of FISSURE Universe Episode 4 - GosuGamers
Mon, 30 Dec 2024
Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study - BMC Cancer
Thu, 29 Aug 2024
Intravesical instillation of CRISPR-Cas13a and fenbendazole nanoparticle formulations shows synergy in bladder cancer model - BioWorld MedTech
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
